


Auditorium G Agnelli

How to reach the Lingotto district:

- **From Lingotto railway station:** on foot follow Via Pannunzio, turn left in Via Passobuole then turn left again in Via Nizza. Estimated time: 20 minutes.
- **From Porta Nuova main railway station:** bus n. 1 or 35, get off after 12 stops. Estimated time: 20 minutes.
- **From Porta Susa railway station:** bus n. 1 and get off at Via Nizza/Via Vado stop. Estimated time: 30 minutes.

Lingotto Conference Centre main access:

- **Pedestrian entrance:** Via Nizza n. 280.



Putting evidence into practice: optimising outcomes for patients with NSCLC

PILC

Invitation

11.50–13.20

Saturday 12 March 2011

Auditorium G Agnelli

Lingotto Conference and Exhibition Centre, Torino, Italy

Avastin[®] and Tarceva[®] satellite symposium held in
conjunction with the Perspectives in Lung Cancer: 12th
European Congress

Dear colleague,

I am pleased to invite you to the Roche-sponsored satellite symposium 'Putting evidence into practice: optimising outcomes for patients with NSCLC', which will be held on Saturday 12 March in Torino, Italy, in conjunction with the Perspectives in Lung Cancer: 12th European Congress.

Over recent years, there has been an expansion in the number of therapeutic options for first-line and later lines of treatment for advanced non-small-cell lung cancer (NSCLC). During this symposium we will take a closer look at how molecularly targeted therapies are changing the way we treat patients with NSCLC. Our distinguished international faculty will discuss the latest clinical data for current treatment options in NSCLC, including the vascular endothelial growth factor (VEGF) inhibitor, Avastin® (bevacizumab), and the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor, Tarceva® (erlotinib). We will also discuss the impact of these data on current clinical practice and how we can further expand and optimise treatment options in the future.

We hope that you will be able to join us in Torino for what promises to be a highly informative and stimulating meeting.

Yours sincerely,



**Professor
Nick Thatcher**
Chair



**Professor
Ed Kim**



**Professor
Kostas Syrigos**

Lung Cancer Satellite Symposium

Programme

- 11.50** **Chair's welcome and introduction**
Nick Thatcher (UK)
- 12.00** **Optimising first-line treatment in NSCLC**
Ed Kim (USA)
- 12.30** **Challenges and opportunities in post-platinum therapy**
Nick Thatcher (UK)
- 12.55** **Novel treatment options for NSCLC**
Kostas Syrigos (Greece)
- 13.05** **Q&A**
- 13.15** **Chair's summary and close**
Nick Thatcher (UK)